Latest Vestal Point Capital, LP Stock Portfolio
Vestal Point Capital, LP Performance:
2025 Q3: 19.59%YTD: 1.62%2024: -12.47%
Performance for 2025 Q3 is 19.59%, and YTD is 1.62%, and 2024 is -12.47%.
About Vestal Point Capital, LP and 13F Hedge Fund Stock Holdings
Vestal Point Capital, LP is a hedge fund based in NEW YORK, NY. On 10-Aug-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $1.3 Billions. In it's latest 13F Holdings report, Vestal Point Capital, LP reported an equity portfolio of $2.2 Billions as of 30 Sep, 2025.
The top stock holdings of Vestal Point Capital, LP are , ACLX, NUVL. The fund has invested 5.4% of it's portfolio in ASCENDIS PHARMA A/S and 4.6% of portfolio in ARCELLX INC.
The fund managers got completely rid off GE HEALTHCARE TECHNOLOGIES INC, MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and COOPER COS INC/THE (COO) stocks. They significantly reduced their stock positions in UNIQURE NV (QURE), EXACT SCIENCES CORP (EXAS) and KALVISTA PHARMACEUTICALS INC (KALV). Vestal Point Capital, LP opened new stock positions in ABIVAX SA, REPLIGEN CORP (RGEN) and DEXCOM INC (DXCM). The fund showed a lot of confidence in some stocks as they added substantially to BECTON DICKINSON & CO (BDX), ENLIVEN THERAPEUTICS INC and DYNE THERAPEUTICS INC (DYN).
The top stock holdings of Vestal Point Capital, LP are , ACLX, NUVL. The fund has invested 5.4% of it's portfolio in ASCENDIS PHARMA A/S and 4.6% of portfolio in ARCELLX INC.
The fund managers got completely rid off GE HEALTHCARE TECHNOLOGIES INC, MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and COOPER COS INC/THE (COO) stocks. They significantly reduced their stock positions in UNIQURE NV (QURE), EXACT SCIENCES CORP (EXAS) and KALVISTA PHARMACEUTICALS INC (KALV). Vestal Point Capital, LP opened new stock positions in ABIVAX SA, REPLIGEN CORP (RGEN) and DEXCOM INC (DXCM). The fund showed a lot of confidence in some stocks as they added substantially to BECTON DICKINSON & CO (BDX), ENLIVEN THERAPEUTICS INC and DYNE THERAPEUTICS INC (DYN).
Vestal Point Capital, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Vestal Point Capital, LP made a return of 19.59% in the last quarter. In trailing 12 months, it's portfolio return was -7.16%.
New Buys
| Ticker | $ Bought |
|---|---|
| abivax sa | 84,900,000 |
| repligen corp | 53,468,000 |
| dexcom inc | 43,738,500 |
| biogen inc | 38,522,000 |
| rapport therapeutics inc | 28,215,000 |
| belite bio inc | 23,125,000 |
| ultragenyx pharmaceutical inc | 22,560,000 |
| axsome therapeutics inc | 18,217,500 |
New stocks bought by Vestal Point Capital, LP
Additions
| Ticker | % Inc. |
|---|---|
| becton dickinson & co | 1,200 |
| enliven therapeutics inc | 364 |
| dyne therapeutics inc | 281 |
| disc medicine inc | 257 |
| lantheus holdings inc | 240 |
| danaher corp | 200 |
| ascendis pharma a/s | 200 |
| globus medical inc | 150 |
Additions to existing portfolio by Vestal Point Capital, LP
Reductions
| Ticker | % Reduced |
|---|---|
| uniqure nv | -93.92 |
| exact sciences corp | -89.29 |
| kalvista pharmaceuticals inc | -83.96 |
| cytokinetics inc | -75.63 |
| vera therapeutics inc | -75.48 |
| savara inc | -63.55 |
| dianthus therapeutics inc | -63.12 |
| jazz pharmaceuticals plc | -58.33 |
Vestal Point Capital, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cogent biosciences inc | -22,114,400 |
| structure therapeutics inc | -24,888,000 |
| ge healthcare technologies inc | -51,849,000 |
| perrigo co plc | -16,700,000 |
| moonlake immunotherapeutics | -25,960,000 |
| travere therapeutics inc | -5,254,000 |
| cooper cos inc/the | -24,906,000 |
| passage bio inc | -2,441,830 |
Vestal Point Capital, LP got rid off the above stocks
Sector Distribution
Vestal Point Capital, LP has about 69.1% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 69.1 |
| Others | 30.9 |
Market Cap. Distribution
Vestal Point Capital, LP has about 12.2% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 40 |
| UNALLOCATED | 30.9 |
| SMALL-CAP | 13.8 |
| LARGE-CAP | 12.2 |
| MICRO-CAP | 2.8 |
Stocks belong to which Index?
About 46.3% of the stocks held by Vestal Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 53.7 |
| RUSSELL 2000 | 36.3 |
| S&P 500 | 10 |
Vestal Point Capital, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Vestal Point Capital, LP
Vestal Point Capital, LP has 80 stocks in it's portfolio. About 38.3% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. QURE was the most profitable stock for Vestal Point Capital, LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABT | abbott laboratories | 1.51 | 250,000 | 33,485,000 | added | 42.86 | ||
| ACLX | arcellx inc | 4.63 | 1,250,000 | 102,625,000 | reduced | -54.55 | ||
| AGIO | agios pharmaceuticals inc | 0.23 | 127,000 | 5,097,780 | new | |||
| ALEC | alector inc | 0.13 | 980,000 | 2,900,800 | added | 0.31 | ||
| APLT | applied therapeutics inc | 0.39 | 14,250,000 | 8,619,820 | added | 23.91 | ||
| ARQT | arcutis biotherapeutics inc | 0.17 | 200,000 | 3,770,000 | added | 110 | ||
| ATRA | atara biotherapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ATXS | astria therapeutics inc | 1.63 | 4,956,000 | 36,079,700 | added | 9.6 | ||
| AXSM | axsome therapeutics inc | 0.82 | 150,000 | 18,217,500 | new | |||
| BDTX | black diamond therapeutics inc | 0.95 | 5,550,000 | 21,034,500 | reduced | -0.89 | ||
| BDX | becton dickinson & co | 2.75 | 325,000 | 60,830,200 | added | 1,200 | ||
| BIIB | biogen inc | 1.74 | 275,000 | 38,522,000 | new | |||
| BMRN | biomarin pharmaceutical inc | 2.03 | 830,000 | 44,952,800 | added | 66.00 | ||
| BRKR | bruker corp | 0.65 | 440,000 | 14,295,600 | reduced | -12.00 | ||
| CARA | tvardi therapeutics inc | 0.29 | 167,000 | 6,507,990 | new | |||
| CDTX | cidara therapeutics inc | 1.73 | 400,000 | 38,304,000 | reduced | -20.00 | ||
| CLDX | celldex therapeutics inc | 1.41 | 1,205,000 | 31,173,400 | reduced | -31.14 | ||
| COGT | cogent biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| COO | cooper cos inc/the | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRNX | crinetics pharmaceuticals inc | 1.41 | 750,000 | 31,237,500 | reduced | -50.00 | ||